The alfapump® system is currently not approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe, the United States or Canada.

Sequana Medical presented the alfapump® system at this year’s Viszeralmedizin Congress in Leipzig, Germany

Sequana Medical was delighted to present the alfapump system for the third time at this year’s nationwide Viszeralmedizin Congress, organised by the DGVS (German Society for Gastroenterology, Digestive and Metabolic Diseases) and the DGAV (German Society for General and Visceral Surgery), held in Leipzig’s CCL Congress Centre.

This year, we were proud to organise a satellite symposium with speakers Prof Berg from Leipzig, Prof Geier from Würzburg and Dr Manekeller from Bonn. These experienced alfapump users and experts in the field of hepatology presented real world data on the alfapump system (PMSR), tips and tricks for the implantation of an alfapump system and the use of alfapump vs. TIPS. With 100 interested symposium visitors the lecture was a great success.

Related Posts

Leave a Reply